share_log

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

S-8:員工福利計劃證券登記
美股sec公告 ·  06/05 15:02
Moomoo AI 已提取核心訊息
Clene Inc., a biopharmaceutical company, has filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC) on June 5, 2024. The filing is intended to register an additional 30 million shares of common stock under the Clene Inc. Amended 2020 Stock Plan. This move follows the approval by the company's Board of Directors on April 3, 2024, and by its stockholders on May 29, 2024, to increase the number of shares reserved for issuance from 18.4 million to 48.4 million. The registration statement includes references to prior filings and incorporates by reference the contents of the company's previous registration statements filed on March 29, 2021, and June 16, 2023. The company, headquartered in Salt Lake City, Utah, has designated Robert Etherington, its President and CEO, as the agent for service in this filing.
Clene Inc., a biopharmaceutical company, has filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC) on June 5, 2024. The filing is intended to register an additional 30 million shares of common stock under the Clene Inc. Amended 2020 Stock Plan. This move follows the approval by the company's Board of Directors on April 3, 2024, and by its stockholders on May 29, 2024, to increase the number of shares reserved for issuance from 18.4 million to 48.4 million. The registration statement includes references to prior filings and incorporates by reference the contents of the company's previous registration statements filed on March 29, 2021, and June 16, 2023. The company, headquartered in Salt Lake City, Utah, has designated Robert Etherington, its President and CEO, as the agent for service in this filing.
2024年6月5日,生物製藥公司Clene Inc.向證券交易所(SEC)提交了S-8表格的註冊申報。該申報旨在在Clene Inc. Amended 2020 Stock Plan下注冊額外的3000萬股普通股。此舉是在董事會於2024年4月3日和股東於2024年5月29日批准將股份發行數量從1840萬股增加到4840萬股後提出的。註冊聲明包括對之前申報的引用,並借鑑了公司先前在2021年3月29日和2023年6月16日提交的註冊聲明的內容。總部位於猶他州鹽湖城的該公司指定其總裁兼首席執行官Robert Etherington作爲本申報中的服務代理。
2024年6月5日,生物製藥公司Clene Inc.向證券交易所(SEC)提交了S-8表格的註冊申報。該申報旨在在Clene Inc. Amended 2020 Stock Plan下注冊額外的3000萬股普通股。此舉是在董事會於2024年4月3日和股東於2024年5月29日批准將股份發行數量從1840萬股增加到4840萬股後提出的。註冊聲明包括對之前申報的引用,並借鑑了公司先前在2021年3月29日和2023年6月16日提交的註冊聲明的內容。總部位於猶他州鹽湖城的該公司指定其總裁兼首席執行官Robert Etherington作爲本申報中的服務代理。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息